NAFDAC approves production of Chloroquine for ' clinical trial treatment ' of COVID-19  The Director-General of the National Agency for Food and Drug Administration and Control ( NAFDAC ) , Prof Mojisola Adeyeye , said on Monday the agency had ordered the manufacturing of Chloroquine for use in the experimental treatment of coronavirus .
The NAFDAC chief said in a statement the drug was being repurposed for the experimental treatment of the disease .
Adeyeye said some countries had started using Chloroquine for the treatment of COVID-19 , adding that the drug was used in China with moderate success .
The statement read :  " Other researchers in France and the United States have used the drug for the clinical trial treatment of COVID-19 and they reported effectiveness of the drug .
Lagos State will start a clinical trial on chloroquine to evaluate the effectiveness .
" In a very recent publication , chloroquine was reported in a press briefing by the State Council of China , indicating that chloroquine phosphate had demonstrated marked efficacy and acceptable safety in treating COVID-19 associated pneumonia in multi-center clinical trials conducted in China .
@ @ @ @ @ @ @ @ @ @ , Guangzhou , Beijing , Shanghai , Chongqing and Ningbo , and 100 patients .
The investigators reported that Chloroquine phosphate is superior to the control in inhibiting the pneumonia associated with COVID-19 , and shortening the course of the disease .
"  " About four weeks ago , I approached a local manufacturing company ( May and Baker ) , a member of Pharmaceutical Manufacturing Group of Manufacturing Association of Nigeria ( PMGMAN ) , whose flagship product in the past was chloroquine to make a batch of the drug for emergency stock .
" The company had NAFDAC approval for the production of the drug as anti-malarial many years ago before the discontinuation .
